Jasper Therapeutics Yönetim

Yönetim kriter kontrolleri 2/4

Jasper Therapeutics CEO'su Ron Martell, Mar2022 tarihinde atandı, in görev süresi 2.67 yıldır. in toplam yıllık tazminatı $ 3.37M olup, şirket hissesi ve opsiyonları dahil olmak üzere 20.6% maaş ve 79.4% ikramiyelerden oluşmaktadır. şirketin hisselerinin 0.22% ine doğrudan sahiptir ve bu hisseler $ 704.43K değerindedir. Yönetim ekibinin ve yönetim kurulunun ortalama görev süresi sırasıyla 2.3 yıl ve 2.2 yıldır.

Anahtar bilgiler

Ron Martell

İcra Kurulu Başkanı

US$3.4m

Toplam tazminat

CEO maaş yüzdesi	20.6%
CEO görev süresi	2.7yrs
CEO sahipliği	0.2%
Yönetim ortalama görev süresi	2.3yrs
Yönetim Kurulu ortalama görev süresi	2.2yrs

Son yönetim güncellemeleri

Recent updates

We're Keeping An Eye On Jasper Therapeutics' (NASDAQ:JSPR) Cash Burn Rate

Aug 30

We Think Jasper Therapeutics (NASDAQ:JSPR) Needs To Drive Business Growth Carefully

Jan 23

Companies Like Jasper Therapeutics (NASDAQ:JSPR) Are In A Position To Invest In Growth

Jul 31

Jasper Therapeutics: Advancing Cures With HSC Transplants And Safer Prior Conditioning

Nov 28

We Think Jasper Therapeutics (NASDAQ:JSPR) Can Afford To Drive Business Growth

Nov 23

CEO Tazminat Analizi

Ron Martell'un ücretlendirmesi Jasper Therapeutics'un kazancına kıyasla nasıl değişti?
Tarih	Toplam Tazminat	Maaş	Şirket Kazançları
Jun 30 2024	n/a	n/a	-US$62m
Mar 31 2024	n/a	n/a	-US$64m
Dec 31 2023	US$3m	US$695k	-US$64m
Sep 30 2023	n/a	n/a	-US$61m
Jun 30 2023	n/a	n/a	-US$55m
Mar 31 2023	n/a	n/a	-US$50m
Dec 31 2022	US$6m	US$510k	-US$38m

Tazminat ve Piyasa: Ron 'nin toplam tazminatı ($USD 3.37M ), US pazarındaki benzer büyüklükteki şirketler için ortalamanın üzerindedir ($USD 2.40M ).

Tazminat ve Kazançlar: Ron 'in tazminatı, şirketin son bir yıldaki performansıyla tutarlıydı.

CEO

Ron Martell (62 yo)

2.7yrs

Görev süresi

US$3,369,990

Tazminat

Mr. Ronald A. Martell, also known as Ron, serves as President, Chief Executive Officer & Director at Jasper Therapeutics, Inc. since March 15, 2022. He has been Chief Financial Officer and Director at Morp...

Liderlik Ekibi

İsim	Pozisyon	Görev süresi	Tazminat	Sahiplik
Ronald Martell	President	2.7yrs	US$3.37m	0.22% $ 704.4k
Judith Shizuru	Co-Founder & Director	no data	US$357.71k	0.77% $ 2.5m
Jeetinder Mahal	Chief Operating Officer	2.7yrs	US$1.18m	0.17% $ 531.9k
Edwin Tucker	Chief Medical Officer	1.4yrs	US$977.73k	0.0027% $ 8.5k
Herbert Cross	CFO & Corporate Secretary	1.2yrs	Veri yok	Veri yok
Luca Di Noto	Senior Vice President of Technical Operations	4.8yrs	Veri yok	Veri yok
David Ku	Vice President of Corporate Development	no data	Veri yok	Veri yok
Matthew Ford	Vice President of Human Resources	1.8yrs	Veri yok	Veri yok
Wendy Pang	Senior Vice President of Research & Translational Medicine	2.7yrs	Veri yok	Veri yok
Patricia Carlos	Senior Vice President of Regulatory Affairs & Quality	1.3yrs	Veri yok	Veri yok

2.3yrs

Ortalama Görev Süresi

52yo

Ortalama Yaş

Deneyimli Yönetim: JSPR 'un yönetim ekibi deneyimli olarak değerlendirilmektedir (ortalama görev süresi 2.3 yıldır).

Yönetim Kurulu Üyeleri

İsim	Pozisyon	Görev süresi	Tazminat	Sahiplik
Ronald Martell	President	2.7yrs	US$3.37m	0.22% $ 704.4k
Judith Shizuru	Co-Founder & Director	6.7yrs	US$357.71k	0.77% $ 2.5m
Thomas Wiggans	Independent Chairman	less than a year	US$76.47k	0.033% $ 106.3k
Kurt von Emster	Independent Director	5yrs	US$128.21k	0.014% $ 45.0k
Daniel Adelman	Member of Scientific Advisory Board & Senior Clinical Advisor	1.4yrs	Veri yok	Veri yok
Arthur Weiss	Member of Scientific Advisory Board	no data	Veri yok	Veri yok
Frederick Appelbaum	Member of Scientific Advisory Board	no data	Veri yok	Veri yok
Jeffrey Ravetch	Member of Scientific Advisory Board	no data	Veri yok	Veri yok
Stephen Galli	Member of Scientific Advisory Board	1.5yrs	Veri yok	Veri yok
Vishal Kapoor	Independent Director	1.8yrs	US$266.47k	0.029% $ 93.0k
Harry Malech	Member of Scientific Advisory Board	no data	Veri yok	Veri yok
Christian Nolet	Independent Director	3.2yrs	US$126.41k	0.022% $ 69.1k

2.2yrs

Ortalama Görev Süresi

67yo

Ortalama Yaş

Deneyimli Yönetim Kurulu: JSPR 'nin yönetim kurulu üyeleri deneyimli olarak kabul edilmiyor ( 2.2 yıllık ortalama görev süresi), bu da yeni bir yönetim kurulu olduğunu gösteriyor.

Jasper Therapeutics Yönetim

Yönetim kriter kontrolleri 2/4

Anahtar bilgiler

Son yönetim güncellemeleri

Jasper Therapeutics, Inc. Announces Board Changes

Jasper Therapeutics, Inc., Annual General Meeting, Jun 06, 2024

Less than half of directors are independent

Jasper Therapeutics, Inc. Announces Board Changes

Jasper Therapeutics, Inc. Announces Chief Financial Officer Changes

Jasper Therapeutics Strengthens Management Team with Key Appointments

Recent updates

Jasper Therapeutics, Inc. Reports Positive Data from Spotlight Study of Briquilimab in Chronic Inducible Urticaria

New minor risk - Share price stability

We're Keeping An Eye On Jasper Therapeutics' (NASDAQ:JSPR) Cash Burn Rate

Price target increased by 7.7% to US$69.13

Jasper Therapeutics, Inc. Announces Board Changes

Jasper Therapeutics, Inc. to Present Data on Briquilimab in Mast Cell Driven Diseases at the EAACI Congress 2024

Asper Therapeutics, Inc Announces the Expansion of its Mast Cell Development Portfolio with Phase 1b/2a Study Evaluating Briquilimab in Asthma Patients

Jasper Therapeutics, Inc., Annual General Meeting, Jun 06, 2024

Jasper Therapeutics, Inc. Announces First Patient Dosed in Phase 1b/2a SPOTLIGHT Clinical Study of Briquilimab in Chronic Inducible Urticaria

Jasper Therapeutics, Inc. Announces Additional Positive Phase 1b/2a Data on Briquilimab as A Conditioning Agent in the Treatment of Fanconi Anemia

Jasper Therapeutics, Inc. has filed a Follow-on Equity Offering in the amount of $50.505 million.

New major risk - Share price stability

Jasper Therapeutics, Inc. has completed a Follow-on Equity Offering in the amount of $50.505 million.

We Think Jasper Therapeutics (NASDAQ:JSPR) Needs To Drive Business Growth Carefully

Price target decreased by 11% to US$61.25

Jasper Therapeutics Announces Reverse Stock Split to Regain Compliance with the Minimum Bid Price Requirement of Common Stock for Continued Listing on the Nasdaq Capital Market

Jasper Therapeutics, Inc. Presents Positive Final Results from Phase 1 Study of Briquilimab in Patients with AML or MDS Undergoing Hematopoietic Cell Transplant in Oral Presentation At ASH 2023

Jasper Therapeutics, Inc. Announces First Patient Dosed in Phase 1B/2A Clinical Study of Briquilimab in Chronic Spontaneous Urticaria

Less than half of directors are independent

Jasper Therapeutics Announces Oral Presentation of Positive Final Results from Phase 1 Study of Briquilimab in Patients with AML or MDS Undergoing Hematopoietic Cell Transplant at ASH 2023

Jasper Therapeutics, Inc. Announces Board Changes

Jasper Therapeutics Receives Written Notice from Nasdaq Regarding Minimum $1.00 Per Share Requirement

Jasper Therapeutics, Inc. Announces Chief Financial Officer Changes

Price target increased by 9.8% to US$6.88

New major risk - Revenue and earnings growth

Jasper Therapeutics Strengthens Management Team with Key Appointments

Companies Like Jasper Therapeutics (NASDAQ:JSPR) Are In A Position To Invest In Growth

Jasper Therapeutics, Inc. Announces First Patient Dosed in A Phase 1 Trial of Briquilimab in Lower-Risk Myelodysplastic Syndrome

Jasper Therapeutics, Inc. Appoints Scott Brun to Its Board of Directors

CFO, COO & Corporate Secretary notifies of intention to sell stock

Jasper Therapeutics, Inc. Announces Appointment of Edwin J. Tucker as Chief Medical Officer

Jasper Therapeutics, Inc. Announces Appointment of Stephen J. Galli to Scientific Advisory Board

Jasper Therapeutics, Inc. Appoints Vishal Kapoor as Class I Director

Price target increased by 11% to US$5.97

We're Keeping An Eye On Jasper Therapeutics' (NASDAQ:JSPR) Cash Burn Rate

Price target decreased by 9.0% to US$7.10

Jasper Therapeutics, Inc. Announces New Positive Briquilimab Data to Be Presented at the 2023 Tandem Meetings

Jasper Therapeutics, Inc. Announces Development Prioritization of Briquilimab in Chronic Diseases

Jasper Therapeutics Announces European Union Orphan Drug Designation for Briquilimab as A Conditioning Treatment for Patients Prior to Receiving A Stem Cell Transplant

Jasper Therapeutics, Inc. Announces Positive Clinical Data from A Phase I/Ii Trial of Briquilimab as A Conditioning Treatment in Sickle Cell Disease and Beta Thalassemia

Price target decreased to US$7.80

High number of new directors

Price target decreased to US$12.00

Jasper Therapeutics Receives Written Notice from Nasdaq

Jasper Therapeutics (NASDAQ:JSPR) Will Have To Spend Its Cash Wisely

Jasper Therapeutics Announces Positive Clinical Data from Investigator Sponsored Study of JSP191 Conditioning in Fanconi Anemia Patients at IEWP Annual Meeting

Jasper Therapeutics Announces FDA Fast Track Designation for JSP191, A Novel Monoclonal Antibody Targeting CD117, in the Treatment of Patients with Severe Combined Immunodeficiency (SCID) Undergoing Allogeneic Hematopoietic Stem Cell Transplant

Price target decreased to US$12.25

Jasper Therapeutics GAAP EPS of -$0.29 beats by $0.02

Non-Executive Chairperson of the Board notifies of intention to sell stock

Is Jasper Therapeutics (NASDAQ:JSPR) In A Good Position To Invest In Growth?

Jasper Therapeutics Announces Treatment of First Patient in Study of JSP191 Conditioning in Patients with Fanconi Anemia

Jasper Therapeutics, Inc. Announces Development of Novel Curative Therapies Based on the Biology of the Hematopoietic Stem Cell

Jasper Therapeutics, Inc., Annual General Meeting, Jun 23, 2022

High number of new directors

Jasper Therapeutics, Inc. Announces Updated Data from Phase 1 Clinical Trial of JSP191 as Targeted Stem Cell Conditioning Agent in Older Patients with Myelodysplastic Syndromes or Acute Myeloid Leukemia Undergoing Hematopoietic Cell Transplantation

High number of new directors

Jasper Therapeutics, Inc. Announces Executive Changes

Jasper Therapeutics: Advancing Cures With HSC Transplants And Safer Prior Conditioning

We Think Jasper Therapeutics (NASDAQ:JSPR) Can Afford To Drive Business Growth

No independent directors

CEO Tazminat Analizi

CEO

Görev süresi

Tazminat

Liderlik Ekibi

Ortalama Görev Süresi

Ortalama Yaş

Yönetim Kurulu Üyeleri